Inventor

STRUCK JOACHIM

DE66 patents

⚠️ This page may combine multiple inventors who share the name “STRUCK JOACHIM”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

STRUCK JOACHIM

BERGMANN ANDREAS

Diagnosis and risk stratification using NT-proET-1

Method for the determination of the formation of endothelins for medical diagnostic purposes, and antibodies and kits for carrying out such a method

Diagnosis and risk stratification by determining the marker CT-proADM

Method for the determination of the formation of endothelins for medical diagnostic purposes, and antibodies and kits for carrying out such a method

Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists

Method for the detection of sepsis by determining peptide prohormone levels

Procalcitonin-based diagnosis of infections or inflammatory diseases of the respiratory tract in a patient with heart failure

Diagnosis and risk stratification of cardiac insufficiency by means of natriuretic peptides for NYHA I patients

Vasoactive hormone-based stratification of patients suffering from diseases related to endothelial function/dysfunction

Diagnosis and risk classification of acute coronary syndrome by means of CT-proET-1 in combination with NT-proBNP

Determination of short-chain SRL alcohol dehydrogenase (DHRS4) as a biomarker for inflammations and infections

Determination of a midregional proadrenomedullin partial peptide in biological fluids for diagnostic purposes, and immunoassays for carrying out such a determination

Method for detecting analytes

Method for determining amino-terminal proANP in patients having a cardiac disease or being suspected of developing or having a cardiac disease

Risk stratification for acute coronary syndrome by determining copeptin

Use of carbamoyl phosphate synthetase 1 (CPS) as a humoral biomarker for the diagnosis of tumour diseases and chronic inflammatory intestinal diseases

In vitro method for the detection of early-stage liver damage

Method for risk stratification in stable coronary artery disease

BRAHMS GMBH

Antibodies for the selective determination of procalcitonin 1-116

Method for determining sepsis using pro-ADM

Determination of a midregional proadrenomedullin partial peptide in biological fluids for diagnostic purposes, and immunoassays for carrying out such a determination

Sandwich immunoassay for identifying partial proANP peptides

Prognosis of adverse events in patients with suspected chronic heart failure

Use of procalcitonin (PCT) in risk stratification and prognosis of patients with a primary, non-infectious disease

Method for determining sepsis using pro-BNP

Method of obtaining a binder to prepro-vasopressin or fragments thereof

Diagnosis and risk stratification by determining the marker CT-proADM

Method for risk stratification in stable coronary artery disease

Procalcitonin for the prognosis of adverse events

Immunoassay for the detection of procalcitonin

Risk assessment for antibiotics treatment in patients suffering from primary non-infectious disease by determining the level of procalcitonin

BRAHMS AG

Method and substances for diagnosis and therapy of sepsis and sepsis-like systemic infections

Diagnostic method for disorders using copeptin

Receptor binding assay for detecting TSH-receptor auto-antibodies

Method for the detection of sepsis using procalcitonin-3-116

Method for determining sepsis using pro-ANF

Uses of aldose-1-epimerase (mutarotase) for diagnosis and therapy of inflammatory diseases and sepsis

Inflammation-specific peptides and the uses thereof

Use of soluble cytokeratin-1-fragments in diagnostics and therapy

Uses of carbamoyl phosphate synthetase for the diagnois of inflammatory diseases and sepsis

CHP for use as marker for sepsis-type inflammatory diseases

Method for diagnosing inflammatory diseases and infections by the determination of LASP-1 immunoreactivity

Receptor binding assays and reagent kit for detecting TSH receptor autoantibodies

BRAHMS DIAGNOSTICA GMBH

Method for the determination of anti-TSH receptor autoantibodies

Determination of free thyroid hormones by competitive immunoassay

Method for the detecting thyroid autoantibodies

STRUCK JOACHIM

Marker for graft failure and mortality

Use of procalcitonin (PCT) in risk stratification and prognosis of patients with a primary, non-infectious disease

Arginine vasopressin pro-hormone as predictive biomarker for diabetes

NG LEONG LOKE

Methods of diagnosis and risk stratification of adverse events in post myocardial infarction patients using pro-adrenomedullin